Concourse Financial Group Securities, Inc. Adc Therapeutics Sa Transaction History

Concourse Financial Group Securities, Inc.

$0
Q2 2025

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

100.0%

Previous 100.0%

22 transactions

Quarter	Operation	Price Per share
Q2 2025 Aug 12, 2025	BUY	$1.1 - $3.67 $0 - $0
Q1 2025 May 14, 2025	BUY	$1.39 - $2.02 $0 - $0
Q4 2024 Feb 13, 2025	BUY	$1.89 - $3.48 $0 - $0
Q3 2024 Oct 10, 2024	BUY	$2.59 - $4.01 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$2.55 - $5.09 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$1.66 - $5.29 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$0.47 - $1.79 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$0.72 - $2.37 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$0.72 - $2.37 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$1.9 - $2.66 $0 - $0
Q1 2023 May 15, 2023	BUY	$1.92 - $5.45 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$2.87 - $5.24 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$4.66 - $10.31 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$5.96 - $14.99 $0 - $0
Q1 2022 May 09, 2022	BUY	$13.28 - $20.03 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$19.29 - $31.51 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$20.45 - $30.0 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$20.38 - $27.04 $0 - $0
Q1 2021 May 13, 2021	BUY	$22.75 - $34.05 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$25.26 - $38.02 $0 - $0
Q3 2020 Nov 13, 2020	BUY	$32.87 - $51.05 $0 - $0
Q2 2020 Aug 13, 2020	BUY	$29.65 - $46.81 $0 - $0

Others Institutions Holding ADCT

# of Institutions

Shares Held

67.8M

Call Options Held

68.2K

Put Options Held

75.8K

Redmile Group, LLC San Francisco, CA

15.7M
Shares

$63.3 Million
5.11% of portfolio
Prosight Management, LP Dallas, TX

10.5M
Shares

$42.3 Million
7.6% of portfolio
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct

7.76M
Shares

$31.4 Million
0.05% of portfolio
Orbimed Advisors LLC San Diego, CA

5.91M
Shares

$23.9 Million
0.57% of portfolio
Black Rock Inc. New York, NY

3.55M
Shares

$14.4 Million
0.0% of portfolio

View Full List

About ADC Therapeutics SA

Ticker ADCT
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,645,296
Market Cap $314M
Description
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...

More about ADCT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account